转移性去势抵抗性前列腺癌(mCRPC)的治疗方案及疗效如何？

参考文献

[1] 中国临床肿瘤学会（CSCO）前列腺癌诊疗指南（2023 年）.

[2] Rathkopf DE, et al. Updated interim efficacy analysis and long-term safety of abiraterone

acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy

(COU-AA-302)[J]. Eur Urol. 2014;66(5):815-25.

CN-138528 Expiration Date: 2024-10-9[3] Beer TM, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant

Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study[J]. Eur Urol. 2017;71(2):151-154.

[4] Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced

prostate cancer[J]. N Engl J Med. 2004;351(15):1502-12.

[5] Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl

J Med. 2013;369(3):213-23.

[6] de Bono J, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer[J]. N Engl J Med.

2020;382(22):2091-2102.

[7] Hussain M, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer[J].

N Engl J Med. 2020;383(24):2345-2357.

[8] Khalaf DJ, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone

in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase

2, crossover trial[J]. Lancet Oncol. 2019;20(12):1730-1739.

[9] Brasso K, et al. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant

Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis[J]. Eur

Urol. 2015;68(2):317-24.